An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy - PubMed (original) (raw)
. 2013 Sep;19(9):1114-23.
doi: 10.1038/nm.3291. Epub 2013 Aug 4.
Xiumin Wu, Guanglei Zhuang, Hai Ngu, Ian Kasman, Jianhuan Zhang, Jean-Michel Vernes, Zhaoshi Jiang, Y Gloria Meng, Franklin V Peale, Wenjun Ouyang, Napoleone Ferrara
Affiliations
- PMID: 23913124
- DOI: 10.1038/nm.3291
Free article
An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy
Alicia S Chung et al. Nat Med. 2013 Sep.
Free article
Abstract
Although angiogenesis inhibitors have provided substantial clinical benefit as cancer therapeutics, their use is limited by resistance to their therapeutic effects. While ample evidence indicates that such resistance can be influenced by the tumor microenvironment, the underlying mechanisms remain incompletely understood. Here, we have uncovered a paracrine signaling network between the adaptive and innate immune systems that is associated with resistance in multiple tumor models: lymphoma, lung and colon. Tumor-infiltrating T helper type 17 (T(H)17) cells and interleukin-17 (IL-17) induced the expression of granulocyte colony-stimulating factor (G-CSF) through nuclear factor κB (NF-κB) and extracellular-related kinase (ERK) signaling, leading to immature myeloid-cell mobilization and recruitment into the tumor microenvironment. The occurrence of T(H)17 cells and Bv8-positive granulocytes was also observed in clinical tumor specimens. Tumors resistant to treatment with antibodies to VEGF were rendered sensitive in IL-17 receptor (IL-17R)-knockout hosts deficient in T(H)17 effector function. Furthermore, pharmacological blockade of T(H)17 cell function sensitized resistant tumors to therapy with antibodies to VEGF. These findings indicate that IL-17 promotes tumor resistance to VEGF inhibition, suggesting that immunomodulatory strategies could improve the efficacy of anti-angiogenic therapy.
Comment in
- Tumour microenvironment: Means of resistance.
Seton-Rogers S. Seton-Rogers S. Nat Rev Cancer. 2013 Sep;13(9):607. doi: 10.1038/nrc3588. Nat Rev Cancer. 2013. PMID: 23969688 No abstract available. - IL-17 mediates resistance to anti-VEGF therapy.
Maniati E, Hagemann T. Maniati E, et al. Nat Med. 2013 Sep;19(9):1092-4. doi: 10.1038/nm.3333. Nat Med. 2013. PMID: 24013745
Similar articles
- IL-17 mediates resistance to anti-VEGF therapy.
Maniati E, Hagemann T. Maniati E, et al. Nat Med. 2013 Sep;19(9):1092-4. doi: 10.1038/nm.3333. Nat Med. 2013. PMID: 24013745 - G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models.
Shojaei F, Wu X, Qu X, Kowanetz M, Yu L, Tan M, Meng YG, Ferrara N. Shojaei F, et al. Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6742-7. doi: 10.1073/pnas.0902280106. Epub 2009 Apr 3. Proc Natl Acad Sci U S A. 2009. PMID: 19346489 Free PMC article. - Bv8 regulates myeloid-cell-dependent tumour angiogenesis.
Shojaei F, Wu X, Zhong C, Yu L, Liang XH, Yao J, Blanchard D, Bais C, Peale FV, van Bruggen N, Ho C, Ross J, Tan M, Carano RA, Meng YG, Ferrara N. Shojaei F, et al. Nature. 2007 Dec 6;450(7171):825-31. doi: 10.1038/nature06348. Nature. 2007. PMID: 18064003 - Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells.
Shojaei F, Ferrara N. Shojaei F, et al. Cancer Res. 2008 Jul 15;68(14):5501-4. doi: 10.1158/0008-5472.CAN-08-0925. Cancer Res. 2008. PMID: 18632597 Review. - Recruited bone marrow derived cells, local stromal cells and IL-17 at the front line of resistance development to anti-VEGF targeted therapies.
Darvishi B, Majidzadeh-A K, Ghadirian R, Mosayebzadeh M, Farahmand L. Darvishi B, et al. Life Sci. 2019 Jan 15;217:34-40. doi: 10.1016/j.lfs.2018.11.033. Epub 2018 Nov 22. Life Sci. 2019. PMID: 30472294 Review.
Cited by
- The Role of Interleukins in Colorectal Cancer.
Li J, Huang L, Zhao H, Yan Y, Lu J. Li J, et al. Int J Biol Sci. 2020 Jun 14;16(13):2323-2339. doi: 10.7150/ijbs.46651. eCollection 2020. Int J Biol Sci. 2020. PMID: 32760201 Free PMC article. Review. - Myeloid cell signatures in tumor microenvironment predicts therapeutic response in cancer.
Achyut BR, Arbab AS. Achyut BR, et al. Onco Targets Ther. 2016 Mar 1;9:1047-55. doi: 10.2147/OTT.S102907. eCollection 2016. Onco Targets Ther. 2016. PMID: 27042097 Free PMC article. Review. - NFAT5/STAT3 interaction mediates synergism of high salt with IL-17 towards induction of VEGF-A expression in breast cancer cells.
Amara S, Alotaibi D, Tiriveedhi V. Amara S, et al. Oncol Lett. 2016 Aug;12(2):933-943. doi: 10.3892/ol.2016.4713. Epub 2016 Jun 15. Oncol Lett. 2016. PMID: 27446373 Free PMC article. - Neutrophils in cancer: neutral no more.
Coffelt SB, Wellenstein MD, de Visser KE. Coffelt SB, et al. Nat Rev Cancer. 2016 Jul;16(7):431-46. doi: 10.1038/nrc.2016.52. Epub 2016 Jun 10. Nat Rev Cancer. 2016. PMID: 27282249 Review. - Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion.
Du Four S, Maenhout SK, Benteyn D, De Keersmaecker B, Duerinck J, Thielemans K, Neyns B, Aerts JL. Du Four S, et al. Cancer Immunol Immunother. 2016 Jun;65(6):727-40. doi: 10.1007/s00262-016-1836-3. Epub 2016 Apr 20. Cancer Immunol Immunother. 2016. PMID: 27098427 Free PMC article. Clinical Trial.
References
- Clin Cancer Res. 2009 Apr 15;15(8):2675-84 - PubMed
- J Biol Chem. 2006 Jan 13;281(2):951-61 - PubMed
- Cell Tissue Res. 2009 Jan;335(1):261-9 - PubMed
- J Biol Chem. 2012 Jun 1;287(23):19574-84 - PubMed
- Nature. 2008 Jun 19;453(7198):1051-7 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous